Bausch Health Companies Inc. Debt Securities, Available-for-sale, Current
Bausch Health Companies Inc. (BHC) had Debt Securities, Available-for-sale, Current of $4.41 million as of 2012-12-31, per its 10-K filed 2013-02-28.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2013-02-28
- 2012-12-31: Debt Securities, Available-for-sale, Current $4.41M.
- 2012-03-31: Debt Securities, Available-for-sale, Current $1.05M.
- 2011-12-31: Debt Securities, Available-for-sale, Current $6.34M.
- 2011-09-30: Debt Securities, Available-for-sale, Current $2.97M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2012-12-31 | $4.41M 10-K · filed 2013-02-28 |
| 2012-03-31 | $1.05M 10-Q · filed 2012-05-04 |
| 2011-12-31 | $6.34M 10-K · filed 2013-02-28 |
| 2011-09-30 | $2.97M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $2.95M 10-Q · filed 2011-08-08 |
| 2011-03-31 | $4.30M 10-Q · filed 2011-05-10 |
| 2010-12-31 | $6.08M 10-K · filed 2012-02-29 |
| 2010-09-30 | $5.59M 10-Q · filed 2010-11-05 |
| 2010-06-30 | $6.24M 10-Q · filed 2010-08-06 |
| 2009-12-31 | $9.57M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |